PORTLAND, Ore.--(BUSINESS WIRE)--May 9, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today presented positive preclinical data, resulting from preclinical experiments targeting multiple strains of influenza with NEUGENE® antisense compounds, at the 19th International Conference on Antiviral Research. The presentation, titled “Inhibition of Multiple Influenza A Subtypes with Antisense Phosphorodiamidate Morpholino Oligomers,” detailed confirmatory studies by three independent laboratories, as reported previously, and presented new toxicology, pharmacokinetic and preliminary animal efficacy data.
